Neulasta Onpro: a coup de grâce?

With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.

Saved in:
Bibliographic Details
Published in:The American journal of managed care 2023-03, Vol.29 (3), p.e69-e70
Main Authors: Jensen, Chelsee J, Scheckel, Caleb J, Go, Ronald S, Desai, Aakash, Soefje, Scott A
Format: Article
Language:English
Subjects:
Beneficiaries
Biological products
Biosimilar Pharmaceuticals
Breast cancer
Chemotherapy
Descriptive labeling
FDA approval
Filgrastim - therapeutic use
Health care expenditures
Hematology
Humans
Lung cancer
Lymphoma
Medicare
Neutropenia
Oncology
Ovarian cancer
Patient satisfaction
Pharmacy
Polyethylene Glycols - therapeutic use
Reimbursement
Supply chain management
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
ISSN:1088-0224
1936-2692
DOI:10.37765/AJMC.2023.89331